Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.33 |
| ▸ | KDM5A | P29375 | 1/20 | 0.32 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.32 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.32 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | SHBG | P04278 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL382008 | 0.92 | CNR2 (0.34) | SIGMAR1SLC18A3ESR2CYP1A2LMNA | |
| SCHEMBL29669639 | 0.92 | CNR2 (0.34) | SIGMAR1SLC18A3ESR2CYP1A2LMNA | |
| SCHEMBL10772436 | 0.89 | SIGMAR1 (0.39) | SIGMAR1KDM5AKDM7AKDM4CPHF8 | |
| SCHEMBL330353 | 0.89 | — | — | |
| SCHEMBL7068277 | 0.89 | SIGMAR1 (0.39) | SIGMAR1KDM5AKDM7AKDM4CPHF8 | |
| SCHEMBL11691906 | 0.87 | SIGMAR1 (0.42) | SIGMAR1KDM5AKDM7AKDM4CPHF8 | |
| SCHEMBL1534917 | 0.87 | SIGMAR1 (0.42) | SIGMAR1KDM5AKDM7AKDM4CPHF8 | |
| SCHEMBL11880727 | 0.87 | SIGMAR1 (0.42) | SIGMAR1KDM5AKDM7AKDM4CPHF8 | |
| SCHEMBL330197 | 0.87 | SIGMAR1 (0.42) | SIGMAR1KDM5AKDM7AKDM4CPHF8 | |
| SCHEMBL18421980 | 0.87 | SIGMAR1 (0.37) | SIGMAR1KDM5AKDM7AKDM4CPHF8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10723876-B2 | Thermoplastic resin composition and molded article comprising the same | LOTTE ADVANCED MATERIALS CO., LTD. (KR) | 2020-07-28 | — | — | US | disclosed |
| US-10364348-B2 | Thermoplastic resin composition and molded article comprising the same | LOTTE ADVANCED MATERIALS CO., LTD. (KR) | 2019-07-30 | — | — | US | disclosed |
| EP-3135728-B1 | THERMOPLASTIC RESIN COMPOSITION AND MOLDED ARTICLE COMPRISING THE SAME | LOTTE ADVANCED MAT CO LTD (KR) | 2018-03-07 | — | — | EP | disclosed |
| US-20170058122-A1 | Thermoplastic Resin Composition and Molded Article Comprising the Same | LOTTE ADVANCED MATERIALS CO., LTD. (KR) | 2017-03-02 | — | — | US | disclosed |
| US-20170058121-A1 | Thermoplastic Resin Composition and Molded Article Comprising the Same | LOTTE ADVANCED MATERIALS CO., LTD. (KR) | 2017-03-02 | — | — | US | disclosed |
| EP-3135728-A1 | THERMOPLASTIC RESIN COMPOSITION AND MOLDED ARTICLE COMPRISING THE SAME | Lotte Advanced Materials Co., Ltd. (KR) | 2017-03-01 | — | — | EP | disclosed |
| US-20170029617-A1 | Thermoplastic Resin Composition and Molded Article Comprising the Same | LOTTE ADVANCED MATERIALS CO., LTD. (KR) | 2017-02-02 | — | — | US | disclosed |
| US-7320986-B2 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBOTT LABORTORIES (US) | 2008-01-22 | — | — | US | disclosed |
| EP-1603885-A1 | FUSED TRI AND TETRA-CYCLIC PYRAZOLE KINASE INHIBITORS | Abbott Laboratories (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBVIE INC. | 2004-12-23 | — | — | US | disclosed |
| WO-2004080973-A1 | FUSED TRI AND TETRA-CYCLIC PYRAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2004-09-23 | — | — | WO | disclosed |
| US-5183946-A | Reacting a diol derivative with acetylene in presence of basic catalyst; used as chemical intermediate for producing polyurethane useful as hard durable protective coating after curing | ISP INVESTMENTS INC. (US) | 1993-02-02 | — | — | US | disclosed |
| EP-0456658-A4 | VINYLOXY HYDROXYALKYLCYCLOALKANE AND PREPARATION THEREFOR | — | 1992-10-07 | — | — | EP | disclosed |
| EP-0456658-A1 | VINYLOXY HYDROXYALKYLCYCLOALKANE AND PREPARATION THEREFOR | ISP INVESTMENTS INC. (US) | 1991-11-21 | — | — | EP | disclosed |
| WO-1990009364-A1 | VINYLOXY HYDROXYALKYLCYCLOALKANE AND PREPARATION THEREFOR | GAF CHEMICALS CORPORATION (US) | 1990-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | TK1, MAP3K19, MAP3K20 | SIGMAR1 3709/4885KDM5A 3917/4885KDM7A 2319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.